Genitourinary Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

Genitourinary Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

  • December 2021 •
  • 142 pages •
  • Report ID: 6197413 •
  • Format: PDF
The global genitourinary drugs market is expected to grow at a CAGR of around 4% during 2021-2026.

Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

The genitourinary system includes kidneys, ureters, bladder, urethra, and genital organs, which play a vital role in reproduction and getting rid of waste products from the body. Its functioning can be hampered on account of congenital abnormalities, iatrogenic injuries, cancer, trauma, infections, hydronephrosis, and inflammation. Due to the rising number of individuals suffering from these diseases, there is a rise in the demand for genitourinary drugs across the globe. Genitourinary drugs help treat the reproductive organs, excretory system, and urinary tract conditions. They are also used in the treatment of bladder spasms and erectile dysfunction and suppressing uterine contractions to prevent preterm labor.

Genitourinary Drugs Market Trends:
The increasing risk of genitourinary organ damage represents one of the major factors influencing the growth of the market. Moreover, as genitourinary drugs are effective in treating the pediatric population with chronic kidney failure and urinary tract infections, their sales are increasing around the world. Apart from this, the leading market players are focusing on advancing formulation techniques to introduce drugs that help treat chronic prostate cancer patients who have developed resistance to conventional chemotherapeutic and hormone therapy agents. Furthermore, several multinational companies (MNCs) are collaborating with biopharmaceutical leaders to launch next-generation therapeutics and strengthen their position in the market. This, in confluence with a considerable rise in the number of pipeline drugs in late-stage clinical trials, is contributing to the market growth. Besides this, the increasing funding for research and development (R&D) projects, along with improvements in the healthcare infrastructure sponsored by governing and non-governing agencies of numerous countries, is anticipated to drive the demand for genitourinary drugs in the coming years.

Key Market Segmentation:
the analyst provides an analysis of the key trends in each sub-segment of the global genitourinary drugs market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on indication and product.

Breakup by Indication:
Prostate Cancer
Ovarian Cancer
Bladder Cancer
Cervical Cancer
Renal Cancer
Erectile Dysfunction
Urinary Tract Infections
Urinary Incontinence and Overactive Bladder
Sexually Transmitted Diseases
Interstitial Cystitis
Hematuria
Benign Prostatic Hyperplasia

Breakup by Product:
Urological
Hormonal Therapy
Gynecological
Anti-infectives
Others

Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Allergan plc (AbbVie Inc.), Antares Pharma Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Genentech Inc. (Roche Holding AG), GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc. and Teva Pharmaceutical Industries Ltd. Key Questions Answered in This Report:
How has the global genitourinary drugs market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global genitourinary drugs market?
What are the key regional markets?
What is the breakup of the market based on the indication?
What is the breakup of the market based on the product?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global genitourinary drugs market and who are the key players?
What is the degree of competition in the industry?